Improving the accuracy of blood pressure measuring devices in Australia: a modelled return on investment study.
Journal
Journal of human hypertension
ISSN: 1476-5527
Titre abrégé: J Hum Hypertens
Pays: England
ID NLM: 8811625
Informations de publication
Date de publication:
08 Nov 2023
08 Nov 2023
Historique:
received:
11
12
2022
accepted:
10
07
2023
revised:
20
04
2023
medline:
8
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
aheadofprint
Résumé
The VALID BP project was initiated to increase the availability of validated blood pressure measuring devices (BPMDs). The goal is to eliminate non validated BPMDs and minimise over- and underdiagnosis of hypertension caused by inaccurate readings. This study was undertaken to assess the potential return on investment in the VALID BP project. The Framework to Assess the Impact of Translational Health Research was applied to the VALID BP project. This paper focuses on the implementation of the cost benefit analysis aspect of this framework to monetise past research investment and model future research costs, implementation costs, and benefits. Analysis was based on reasoned assumptions about potential impacts from availability and use of validated BPMDs (assuming an end goal of 100% validated BPMDs available in Australia by 2028) and improved skills leading to more accurate BP measurement. After 5 years, with 20% attribution of benefits, there is a potential $1.14-$1.30 return for every dollar spent if the proportion of validated BPMDs and staff trained in proper BP measurement technique increased from 20% to 60%. After eight years (2020-2028) and assuming universal validation and training coverage, the returns would be between $2.70 and $3.20 per dollar spent (not including cost of side effects of unnecessary medication or downstream patient impacts from unmanaged hypertension). This modelled economic analysis indicates there will be positive downstream economic benefits if the availability of validated BPMDs is increased. The findings support ongoing efforts toward a universal regulatory framework for BPMDs and can be considered within more detailed future economic analyses.
Identifiants
pubmed: 37938294
doi: 10.1038/s41371-023-00866-2
pii: 10.1038/s41371-023-00866-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NSW Ministry of Health (NSW Health)
ID : H20/27963-11
Informations de copyright
© 2023. The Author(s).
Références
Australian Institute of Health and Wellfare. High blood pressure. AIHW, Editor. AIHW: Canberra; 2019.
Parati G, Lombardi C, Pengo M, Bilo G, Ochoa JE. Current challenges for hypertension management: from better hypertension diagnosis to improved patients’ adherence and blood pressure control. Int J Cardiol. 2021;331:262–9.
doi: 10.1016/j.ijcard.2021.01.070
pubmed: 33548384
Gabb GM, Mangoni AA, Anderson CS, Cowley D, Dowden JS, Golledge J, et al. Guideline for the diagnosis and management of hypertension in adults—2016. Med J Aust. 2016;205:85–9.
doi: 10.5694/mja16.00526
pubmed: 27456450
National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults— 2016. Melbourne: National Heart Foundation of Australia; 2016.
Stergiou GS, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, et al. A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. J Hypertens. 2018;36:472–8.
doi: 10.1097/HJH.0000000000001634
pubmed: 29384983
pmcid: 5796427
World Health Organization. WHO technical specifications for automated non-invasive blood pressure measuring devices with cuff. WHO medical device technical series. Geneva: World Health Organization; 2020.
Picone DS, Deshpande RA, Schultz MG, Fonseca R, Campbell NRC, Delles C, et al. Nonvalidated home blood pressure devices dominate the online marketplace in Australia. Hypertension. 2020;75:1593–9.
doi: 10.1161/HYPERTENSIONAHA.120.14719
pubmed: 32275193
Picone DS, Campbell NRC, Schutte AE, Olsen MH, Ordunez P, Whelton PK, et al. Validation of blood pressure devices sold globally. JAMA. 2022;327:680–1.
doi: 10.1001/jama.2021.24464
pubmed: 35166811
pmcid: 8848194
Whelton PK, Picone DS, Padwal R, Campbell NRC, Drawz P, Rakotz MK, et al. Global proliferation and clinical consequences of non-validated automated BP devices. J Hum Hypertens. 2023;37:115–9.
Akpolat T, Dilek M, Aydogdu T, Adibelli Z, Erdem DG, Erdem E. Home sphygmomanometers: validation versus accuracy. Blood Press Monit. 2009;14:26–31.
doi: 10.1097/MBP.0b013e3283262f31
pubmed: 19190492
Hodgkinson JA, Lee MM, Milner S, Bradburn P, Stevens R, Hobbs FR, et al. Accuracy of blood-pressure monitors owned by patients with hypertension (ACCU-RATE study): a cross-sectional, observational study in central England. Br J Gen Pract. 2020;70:e548–54.
doi: 10.3399/bjgp20X710381
pubmed: 32482629
pmcid: 7274541
Ringrose JS, Polley G, McLean D, Thompson A, Morales F, Padwal R. An assessment of the accuracy of home blood pressure monitors when used in device owners. Am J Hypertens. 2017;30:683–9.
doi: 10.1093/ajh/hpx041
pubmed: 28430848
Jung MH, Kim GH, Kim JH, Moon KW, Yoo KD, Rho TH, et al. Reliability of home blood pressure monitoring: in the context of validation and accuracy. Blood Press Monit. 2015;20:215–20.
doi: 10.1097/MBP.0000000000000121
pubmed: 25856420
Picone DS, Deshpande RA, Schultz MG, Fonseca R, Campbell NRC, Delles C, et al. Nonvalidated home blood pressure devices dominate the online marketplace in Australia: major implications for cardiovascular risk management. Hypertension. 2020;75:1593–9.
doi: 10.1161/HYPERTENSIONAHA.120.14719
pubmed: 32275193
Sharman JE, O’Brien E, Alpert B, Schutte AE, Delles C, Hecht Olsen M, et al. Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. J Hypertens. 2020;38:21–9.
doi: 10.1097/HJH.0000000000002246
pubmed: 31790375
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. Lancet. 2016;388:2665–712.
doi: 10.1016/S0140-6736(16)31134-5
pubmed: 27671667
VALID BP Project Team. New Certification Course to Improve BP Measurement. In: League WH, editor. Hong Kong; 2019.
Li J, Frick G, Herberigs K, Matsumura P, Sarkis J, Verberk WJ, et al. Industry perspectives on the global use of validated blood pressure measuring devices. J Hum Hypertens. 2023;37:130–3.
Picone DS, Padwal R, Stergiou GS, Cohen JB, McManus RJ, Eckert S, et al. How to find and use validated blood pressure measuring devices. J Hum Hypertens. 2023;37:108–14.
Ordunez P, Campbell NRC, Giraldo Arcila GP, Angell SY, Lombardi C, Brettler JW. et al. HEARTS in the Americas: innovations for improving hypertension and cardiovascular disease risk management in primary care. Rev Panam Salud Publ. 2022;46:e96.
Ordunez P, Lombardi C, Picone DS, Brady TM, Campbell NRC, Moran AE, et al. HEARTS in the Americas: a global example of using clinically validated automated blood pressure devices in cardiovascular disease prevention and management in primary health care settings. J Hum Hypertens. 2023;37:126–9.
Searles A, Doran C, Attia J, Knight D, Wiggers J, Deeming S, et al. An approach to measuring and encouraging research translation and research impact. Health Res Policy Syst. 2016;14:60.
doi: 10.1186/s12961-016-0131-2
pubmed: 27507300
pmcid: 4979128
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4 edition, Oxford: Oxford Medical Publications, Oxford University Press; 2015.
Australian National University. Academic staff salaries Canberra: ANU; 2021; Available from: https://services.anu.edu.au/human-resources/enterprise-agreement/schedule-1-academic-staff-salary-schedule-0 . Accessed 15 Dec 2021.
University of New South Wales. Human Resources: On Costs Sydney: UNSW; 2021 [Available from: https://www.hr.unsw.edu.au/services/salaries/oncosts.html . Accessed 2022.
Brady TM, Padwal R, Blakeman DE, Farrell M, Frieden TR, Kaur P. et al. Blood Pressure Measurement Device Selection in Low‐resource Settings: Challenges, Compromises, and Routes to Progress. J Clin Hypertens. 2020;22:792–801.
doi: 10.1111/jch.13867
Australian Bureau of Statistics. Australian National Accounts: national income, expenditure and product, In Australia Co, editor. Quarterly estimates of key economic flows in Australia, including gross domestic product (GDP), consumption, investment, income and saving, C.o. Australia: Canberra; 2022.
Wilson N, Nghiem N, Foster R, Cobiac L, Blakely T. Estimating the cost of new public health legislation. Bull World Health Organ. 2012;90:532–9.
doi: 10.2471/BLT.11.097584
pubmed: 22807599
pmcid: 3397705
Therapeutic Goods Administration. Cost recovery implementation statement, TGA, Editor. Canberra, Australia: TGA; 2021.
Australian Bureau of Statistics. Population clock Canberra: ABS; 2022 [Available from: https://www.abs.gov.au/AUSSTATS/abs@.nsf/Web+Pages/Population+Clock?opendocument&ref=HPKI . Accessed 2022.
Ruzicka M, Akbari A, Bruketa E, Kayibanda JF, Baril C, Hiremath S, et al. How accurate are home blood pressure devices in use? A cross-sectional study. PloS One. 2016;11:e0155677.
doi: 10.1371/journal.pone.0155677
pubmed: 27249056
pmcid: 4889144
Australian Pharmaceutical Benefit Scheme, Lisinopril, PBS, Editor. Canberra, Australia: Australian Department of Health; 2022.
Australian Institute of Health and Welfare, Australia’s Health 2016, in Australia’s health series no. 15, AIHW., Editor. AIHW: Canberra; 2017.
Australian Bureau of Statistics. Statistics about life tables for Australia, states and territories and life expectancy at birth estimates for sub-state regions, ABS, Editor. Canberra, Australia: ABS; 2021.
Arredondo A, Zúñiga A. Epidemiologic changes and economic burden of hypertension in Latin America: evidence from Mexico. Am J Hypertens. 2006;19:553–9.
doi: 10.1016/j.amjhyper.2005.10.028
pubmed: 16733225
Hird TR, Zomer E, Owen AJ, Magliano DJ, Liew D, Ademi Z, et al. Productivity burden of hypertension in Australia. Hypertension. 2019;73:777–84.
doi: 10.1161/HYPERTENSIONAHA.118.12606
pubmed: 30798659
Hahn RW, Tetlock PC. Has economic analysis improved regulatory decisions. J Econ Perspect. 2008;22:67–84.
doi: 10.1257/jep.22.1.67
Schlander M. HTA agencies need evidence-informed deliberative processes comment on “use of evidence-informed deliberative processes by health technology assessment agencies around the globe. Int J Health Policy Manag. 2020;10:158–61.
pmcid: 7947902
Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25:10–31.
doi: 10.1016/j.jval.2021.10.008
pubmed: 35031088